Addition Therapeutics emerged from stealth with a $106.5 million financing to advance its Precise RNA‑Mediated Insertion of Transgenes (PRINT) platform, an all‑RNA, lipid nanoparticle‑based approach that leverages retrotransposon biology to insert transgenes at targeted genomic safe sites. The company positioned the platform as a way to sidestep limitations of conventional viral gene‑delivery methods. Addition plans IND‑enabling work and highlighted PRINT’s potential to insert large payloads via RNA‑mediated insertion. Backers include high‑profile investors and philanthropic funders; the company also signaled ambitions to scale LNP manufacturing for clinical programs. If PRINT proves safe and reproducible in humans, it could expand the gene therapy toolbox for chronic and rare diseases by enabling site‑specific, non‑viral insertion. Clinical translation will require rigorous assessment of insertion specificity, off‑target integrations, and immunogenicity from repeated LNP dosing.